PARÂMETROS LABORATORIAIS E A FISIOPATOLOGIA DA SÍNDROME LIPODISTRÓFICA NO TRATAMENTO ANTIRETROVIRAL HIV/AIDS

Abstract

The Acquired Immunodeficiency Syndrome (AIDS) was one of the major causes of death that already exists in our country, but thanks to the great development of research on viral replication, viral, cellular and nutritional dynamics, new drugs were created, thus giving rise to therapy antiretroviral, which in turn increases life expectancy and decreases the mortality of countless HIV-positive patients. However, the prolonged use of these drugs results in metabolic changes that end up causing risks to patients' lives, due to changes in glucose, lipids, poor distribution of body fat and insulin resistance, consequently causing cardiac risks, clinical syndrome. The syndrome having some connection with HIV antiretroviral therapy, it is called the HIV Lipodystrophic Syndrome (SLHIV), mainly characterized by changes in glycemic and lipid indices; however, the pathophysiology for these metabolic changes has not yet been elucidated, therefore, the treatment is complicated and difficult to manage because it does not have a concomitantly defined target site. having a specific drug to treat these complications. The objective of this work is to analyze the possible metabolic alterations in HIV/AIDS patients caused by antiretroviral treatment.